NCT03861481 - A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions

DRUG

Rozanolixizumab

Subjects will receive rozanolixizumab in a specified sequence during the treatment period.

OTHER

Placebo

Subjects will receive placebo in a specified sequence during the treatment period.

Trial Locations (22)

27710

Cidp01 912, Durham

28210

Cidp01 903, Charlotte

30912

Cidp01 907, Augusta

33612

Cidp01 901, Tampa

40536

Cidp01 911, Lexington

85018

Cidp01 902, Phoenix

90033

Cidp01 905, Los Angeles

Unknown

Cidp01 101, Ghent

Cidp01 102, Leuven

Cidp01 103, Liège

Cidp01 302, Copenhagen

Cidp01 402, Bordeaux

Cidp01 404, Nice

Cidp01 401, Strasbourg

Cidp01 501, Berlin

Cidp01 503, Essen

Cidp01 505, Göttingen

Cidp01 502, Würzburg

Cidp01 601, Amsterdam

Cidp01 701, Barcelona

Cidp01 702, Barcelona

Cidp01 802, Sheffield

All Listed Sponsors

lead

UCB Biopharma S.P.R.L.

INDUSTRY